This study is testing a new treatment called VG161, alone or with Nivolumab (Opdivo), for people with hepatocellular carcinoma (a type of liver cancer) or intrahepatic cholangiocarcinoma (a type of bile duct cancer). VG161 is an oncolytic virus, meaning it's designed to infect and kill cancer cells. Researchers want to see how safe and effective these treatments are. You might be able to join if you are 18 or older and have advanced liver or bile duct cancer that has progressed after other treatments. The study will look at how many people respond to the treatment and how long they live without their cancer getting worse. The current recruitment status is unclear.

Study design

This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It plans to enroll about 97 participants in different groups, some receiving VG161 alone and others receiving VG161 with Nivolumab.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track your safety for 12 months and your response to treatment for 12 months. It will also measure how long you live without your cancer getting worse for 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.